Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Among authors: ortega v. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortés J. Pascual T, et al. Among authors: ortega v. NPJ Breast Cancer. 2021 Nov 25;7(1):145. doi: 10.1038/s41523-021-00351-4. NPJ Breast Cancer. 2021. PMID: 34824288 Free PMC article.
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V, Antón A, Garau I, Afonso N, Calvo L, Fernández Y, Martínez-García M, Blanco E, Zamora P, García M, Illarramendi JJ, Rodríguez Sánchez CA, Sampayo M, Aguirre E, Pérez-García JM, Cortés J, Llombart-Cussac A. Ortega V, et al. Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20. Clin Breast Cancer. 2019. PMID: 30679100 Clinical Trial.
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, Paré L, Souza CA, Ortega V, Sammut SJ, Cusco P, Fasani R, Chin SF, Perez-Garcia J, Dienstmann R, Nuciforo P, Villagrasa P, Rubio IT, Prat A, Caldas C. De Mattos-Arruda L, et al. Among authors: ortega v. NPJ Breast Cancer. 2021 Jun 7;7(1):73. doi: 10.1038/s41523-021-00282-0. NPJ Breast Cancer. 2021. PMID: 34099718 Free PMC article.
Management of the axilla in early breast cancer patients in the genomic era.
Oliveira M, Cortés J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz E, Ortega V, Pérez J, Saura C, Vidal M, Rubio IT, Di Cosimo S. Oliveira M, et al. Among authors: ortega v. Ann Oncol. 2013 May;24(5):1163-70. doi: 10.1093/annonc/mds592. Epub 2012 Nov 19. Ann Oncol. 2013. PMID: 23165977 Free article. Review.
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Tripathy D, et al. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. doi: 10.1001/jamaoncol.2022.0514. JAMA Oncol. 2022. PMID: 35552364 Free PMC article. Clinical Trial.
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors.
Travier N, Fonseca-Nunes A, Javierre C, Guillamo E, Arribas L, Peiró I, Buckland G, Moreno F, Urruticoechea A, Oviedo GR, Roca A, Hurtós L, Ortega V, Muñoz M, Garrigós L, Cirauqui B, Del Barco S, Arcusa A, Seguí MA, Borràs JM, Gonzalez CA, Agudo A. Travier N, et al. Among authors: ortega v. Med Oncol. 2014 Jan;31(1):783. doi: 10.1007/s12032-013-0783-5. Epub 2013 Dec 6. Med Oncol. 2014. PMID: 24310809 Clinical Trial.
Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
Marín-Aguilera M, Reig Ò, Lozano JJ, Jiménez N, García-Recio S, Erill N, Gaba L, Tagliapietra A, Ortega V, Carrera G, Colomer A, Gascón P, Mellado B. Marín-Aguilera M, et al. Among authors: ortega v. Oncotarget. 2015 Apr 30;6(12):10604-16. doi: 10.18632/oncotarget.3550. Oncotarget. 2015. PMID: 25871394 Free PMC article.
The beautiful history of pertuzumab.
Perez-Garcia J, Muñoz-Couselo E, Ortega V, Cortes J. Perez-Garcia J, et al. Among authors: ortega v. Expert Rev Anticancer Ther. 2012 Jun;12(6):703-5. doi: 10.1586/era.12.46. Expert Rev Anticancer Ther. 2012. PMID: 22716485 No abstract available.
297 results